# Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System

> **NCT00990418** · PHASE1 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 60 (actual)

## Conditions studied

- Pain, Postoperative

## Interventions

- **DRUG:** Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System

## Key facts

- **NCT ID:** NCT00990418
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00990418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00990418, "Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00990418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*